Found 150 Neoplasms trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Dynamic Nuclear Polarization-MR Spectroscopic Imaging of Hepatocellular Carcinoma Metabolism to Predict Response Following Locoregional or Systemic Therapy
Phase 2
The research study is being conducted to evaluate a new imaging technique for detecting the response of hepatocellular carcinoma (HCC) to locoregional or systemic therapy. Locoregional therapies or LRT are called Transarterial Chemoembolization or TACE, Transarterial Radioembolization or TARE and Microwave Ablation or MWA. Systemic therapies or ST are therapy …
A Study of ATRN-119 In Patients With Advanced Solid Tumors (ATRN)
Phase 1
The study will evaluate the safety profile of escalating doses of continuous daily oral ATRN-119 and to determine the maximum tolerated dose (MTD) and recommended dose. ATRN-119 is a drug that has been developed to treat cancers by taking advantage of genetic mutations found only in the tumor and not …
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
For subjects age 18 years and older who are at an increased risk for HCC and for whom HCC surveillance is appropriate, including subjects with cirrhosis or non-cirrhotic subjects with Hepatitis B. Approximately 3,000 subjects are expected to be enrolled, comprised of approximately 2,222 ultrasound surveillance subjects and 778 subjects …
PMBB ROR Program
The goal of the proposed research is to conduct a Hybrid Type 1 effectiveness-implementation study59 to evaluate eHealth delivery alternatives for pre-disclosure education and return of actionable genetic research results. Aim 1 (Effectiveness of eHealth return of results): To evaluate in a randomized study whether disclosure of actionable genetic results …
Instylla HES Hypervascular Tumor Pivotal Study
This research study is being conducted to determine if a new investigational device (Instylla Hydrogel Embolic system) can be used to treat tumors which have an extensive blood supply. This means that the tumors have many blood vessels feeding them. This product will be used to close blood vessels supplying …
UPCC 06922: A First-in-Human Open-label Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors
Phase 1
Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints)
A Prospective Multicenter Study of Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Subjects with Oligometastatic Tumors in the Lung
The primary objective of the study is to evaluate the safety and effectiveness of the NEUWAVETM FLEX MC Microwave Ablation System and Accessories used in transbronchial ablation procedures for adult subjects with oligometastatic tumors ( 2cm) in the lung. Technique Efficacy: Ablation of the target tumor(s) with the ablation zone …
Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Blood is an easily accessible source of tumor cell free (cf) DNA. Both normal and malignant cells shed DNA into the circulation, and advanced genomics technologies can analyze tumor cfDNA, making blood a source of real-time genomic tumor profiling. For ccRCC patients, peripheral blood will be obtained as part of …
UPCC 33922: An Open-Label Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations
Phase 1
Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints)
A study of ceralasertib (AZD6738) as monotherapy and in combination with other anticancer agents in patients with advanced solid malignancies Module 5 (ceralasertib in combination with AZD5305) (ANGEL)
Penn Gynecologic Oncology is participating in Module 5 for ovarian cancer patients.
